← All trials
NCT07090889
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2025
- Primary completion
- Feb 11, 2026
- Completion date
- Feb 11, 2026
- First posted
- Jul 29, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 64
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kamari Pharma LtdLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.